1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Vaccines: The End of Illness Overview

Vaccines: The End of Illness Overview

  • November 2014
  • -
  • Insight Pharma Reports
  • -
  • 164 pages

New to Insight Pharma Reports is Vaccines: The End of Illness. This report focuses on the most recent vaccine research, emphasizing their reputation as an unmatched tool of efficient healthcare. Their low cost, extended protection and the impossibility of their circumvention through development of resistance on the part of the target pathogen have been longstanding attributes of vaccines. Today, vaccine technology is undergoing a fundamental revolution, taking advantage of the profound understanding of the immune system and its ability to mount protective antibody production and cell-based responses to foreign antigens. Understanding these properties will not only enable the development of innovative diagnostics but also the advancement of therapeutic applications.

Specific Highlights Include:

This report profiles some of the major pharma companies involved in vaccine R&D and a number of biotech companies developing new vaccine products and technologies – including 35 small pharma companies and 8 big pharma companies profiled
The logistics and management of the vaccine industry are increasingly based on partnerships between the private sector (pharma and biotech companies), government agencies (WHO) and large non-profits (such as the Gates Foundation).
An assessment of the future directions of vaccines as innovative medical therapies for a wide range of diseases.
Explores conditions not normally thought to be in purview of vaccination, including substance abuse and neurological disorders such as Alzheimer’s disease and Parkinson’s disease.
Survey of industry experts concerning the political economic and technological future of vaccine technology.
Over 20 pages of pipeline and clinical trial data specific to vaccine targets
Over 30 pages of pipeline and clinical trial data specific to cancer vaccines

Table Of Contents

Vaccines: The End of Illness Overview
Executive Summary
Chapter 1: Introduction
1.1 The History of Vaccination
1.1.1 Ancient
1.1.2. 18th century
1.1.3. 19th century
1.1.3.1. Pasteur
1.1.3.2. Coley's toxins
1.1.4. Mid 20th century
1.2. Vaccines in the Doldrums: late 20th century
1.2.1. Liability issues
1.2.2. Vaccine denialism
1.3. The Current State of Vaccine technology, 2013
1.3.1. WHO
1.3.2. Behemoth players: Bill and Melinda Gates
1.3.3. Big pharma jumps in

Chapter 2: A Cornucopia of Vaccine Technologies
2.1. Vaccine production: eggs versus cell culture
2.2. Cell line options
2.3 Conventional Vaccines
2.4. Adjuvants
2.5. Nanoparticle-based vaccines
2.6. DNA Vaccines
2.7. Vaccines driving T-cell activation
2.8. Dendritic cells

Chapter 3: Vaccine Targets
3.1. Infectious Diseases
3.1.1. Influenza
3.1.2. HSV A and B
3.1.3. C. difficile
3.1.4. HIV
3.1.5. Pneumococcus
3.1.6. Typhoid
3.1.7. Candida
3.1.8. Rabies
3.1.9. Rotavirus
3.1.10. Polio
3.1.11. Malaria
3.1.12. Parasitic diseases
3.1.13. Smallpox
3.1.14. Cholera
3.1.15. Mumps
3.1.16. Diphtheria
3.2. Cancer vaccines
3.2.1. Human papilloma virus
3.2.2. Breast cancer
3.2.3. Pancreatic cancer
3.2.4. Renal cell carcinoma
3.2.5. Melanoma: dendritic cells
3.2.6. Prostate cancer

Chapter 4: Big Pharma Vaccines
4.1. AstraZeneca (Medimmune)
4.2. Baxter
4.3. GSK
4.4. JandJ (Crucel)
4.5. Merck
4.6. Novartis
4.7. Pfizer
4.8. Sanofi

Chapter 5: Small Pharma Vaccines
5.1. AC Immune
5.2. Aeras
5.3. Alphavax
5.4. Astrellas
5.6. Bavarian Nordic
5.7. BiondVax Pharmaceuticals
5.8. Braasch Biotech LLC
5.9. Celldex
5.10. Chrontech
5.11. Emergent Biosolutions
5.12. EpiVax
5.13. GenVec
5.14. GeoVax
5.15. Genocea Biosciences
5.16. Immune Targeting Systems
5.17. Indian Immunologicals Limited
5.18. Inovio
5.19. Inviragen
5.20. Juvaris Biotherapeutics
5.21. Medicago
5.22. Mymetics
5.23. NovaRx
5.24. Novavax
5.25. Nuron
5.26. OPKO
5.27. Profectus Bioscience Inc
5.28. Sinovac
5.29. Sorrento Therapeutics, Inc.
5.30. TapImmune
5.31. Valneva
5.32. VaxInnate
5.33. VaxLiant
5.34. VBI vaccines
5.35. Vical

Chapter 6: Regulatory Issues
6.1. A bumpy road
6.2. Current regulatory status

Chapter 7:The Future of Vaccine technology
7.1. Challenges in delivery and storage
7.2. Dry vaccine technology: Ready for prime time?
7.3. A universal Vaccine
7.4. Outlandish targets
7.4.1. Drug abuse
7.4.2. Obesity
7.4.3. Smoking
7.4.4. Alcoholism
7.4.5. Alzheimer's disease
7.4.6. Parkinson's Disease
7.5. Bioterrorism: A global threat?
7.6. Intellectual Property in the Balance
7.7. A bright future for Vaccines

Chapter 8: Survey of Opinion Concerning Vaccine technology by Members of the Industry

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2017 World Infectious Disease Testing Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales and Volume Forecasts for 100 Microbiology Tests, Supplier Shares, Competitive Strategies, Instrumentation, Technologies, Opportunities

2017 World Infectious Disease Testing Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales and Volume Forecasts for 100 Microbiology Tests, Supplier Shares, Competitive Strategies, Instrumentation, Technologies, Opportunities

  • $ 59500
  • Industry report
  • January 2017
  • by Venture Planning Group

This unique 68-country survey from VPGMarketResearch.com provides data and analysis not available from any other published source. The survey is designed to assist diagnostics industry executives, as well ...

2016 Virology and Bacteriology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales and Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

2016 Virology and Bacteriology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales and Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

  • $ 54501
  • Industry report
  • October 2016
  • by Venture Planning Group

This unique 33-country survey from VPGMarketResearch.com contains over 2,100 pages, 875 tables and provides data and analysis not available from any other published source. The survey is designed to assist ...

2016 Infectious Disease Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

2016 Infectious Disease Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

  • $ 54501
  • Industry report
  • October 2016
  • by Venture Planning Group

This unique 33-country survey from VPGMarketResearch.com contains over 2,100 pages, 875 tables and provides data and analysis not available from any other published source. The survey is designed to assist ...


ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.